Summary & Overview

Cervical Spinal Fusion without CC/MCC: Inpatient Reimbursement Overview

DRG 473 pertains to hospitalizations for cervical spinal fusion without Major Complication or Comorbidity or Complication or Comorbidity and defines the clinical cohort of typical cervical fusion cases. Accurate classification matters for inpatient reimbursement because it determines the standardized Medicare Severity Diagnosis-Related Group payment weight and influences hospital revenue for these surgical episodes.

Cervical Spinal FusionDRG Cervical Spinal Fusion without CC/MCCDRG 473Diagnosis-Related GroupInpatient ReimbursementMedicareSpine SurgeryOrthopedic SurgeryNeurosurgery

DRG 473 Overview

DRG 473 covers hospital admissions for cervical spinal fusion procedures without a Major Complication or Comorbidity or a Complication or Comorbidity. It applies to inpatient episodes where patients undergo cervical fusion for degenerative disease, trauma, deformity, or other indications but do not have coded higher-severity comorbid conditions. This Diagnosis-Related Group matters for Medicare payment because it groups similar resource use and sets the base inpatient reimbursement for these procedures. Correct DRG assignment affects hospital payment and coding validation.

National Payment Rates

Across payers the observed rate range runs from about $370 (BCBS minimum) up to $84K (Anthem maximum), with payer medians clustering between $21K and $38K as shown in the table and chart below. The widest spread appears in Anthem where values span from $390 to $84K. Payer medians are: Blue Cross Blue Shield $21K, UnitedHealth Group $33K, Cigna $37K, Aetna $38K, and Anthem $38K.

Mean Rates by Payer — National — DRG 473

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 473 mean payments range from $38K (Anthem and Blue Cross Blue Shield) up to $59K (Cigna), representing the state’s full payer spread. Cigna’s mean at $59K is the most notable deviation, sitting well above the other state payers and above the national comparison means. Reference the table and chart below for payer-level distributions.

Key Insights for Alaska

Highest-paying payer: Cigna with a mean of $59K; Lowest-paying payers: Anthem and Blue Cross Blue Shield with identical means of $38K.
Alaska’s payer means span a narrow range overall but Cigna’s mean at $59K is meaningfully above the other state payers and also above national means presented, indicating a notable upward deviation from national averages.

Clinical Trials

Acute perioperative optimization trials: studies testing protocols to reduce intraoperative blood loss, anesthesia-related complications, and immediate postoperative respiratory or neurologic events in adults undergoing elective or urgent anterior or posterior cervical fusion without CC/MCC. These trials typically enroll patients with cervical radiculopathy or myelopathy who meet surgical indications but are otherwise without major complications, and they compare specific perioperative bundles (e.g., tailored hemostatic strategies, standardized anesthesia pathways, and early mobilization protocols) versus usual care. Results are relevant to surgeons, anesthesiologists, and hospital payers because improvements can shorten operative time, reduce transfusions and ICU needs, and lower index hospitalization costs and resource utilization for this DRG.
Comparative effectiveness and device/technique trials: randomized or pragmatic studies comparing different surgical approaches, fusion constructs, or adjunct technologies (for example anterior cervical discectomy and fusion versus cervical arthroplasty approaches, or different plating and graft options) in patients without major comorbid complications. These trials focus on metrics such as fusion success, reoperation rates, functional outcomes, and short-term inpatient complications over 30–90 days, enrolling typical DRG 473 patients with degenerative cervical disease. Findings inform surgeons and payers about which techniques yield better outcomes or lower complication and readmission rates for this relatively straightforward fusion population, influencing procedure selection, implant procurement, and bundled-payment pathways.
Post-discharge recovery, rehabilitation, and cost-outcomes studies: prospective cohort or randomized studies evaluating discharge timing, outpatient rehabilitation intensity, pain management strategies (including multimodal opioid-sparing regimens), and home health utilization for patients discharged after cervical fusion without CC/MCC. These studies enroll patients who had uncomplicated cervical fusion and examine recovery trajectories, functional status, opioid consumption, readmissions, and total 30–90 day costs to determine optimal post-acute care pathways. This research is important to providers and payers because it identifies interventions that can reduce readmissions, improve return-to-work rates, and optimize post-acute spending for patients in this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$22K	$110K	$17K	6.8K

Acute perioperative optimization trials: studies testing protocols to reduce intraoperative blood loss, anesthesia-related complications, and immediate postoperative respiratory or neurologic events in adults undergoing elective or urgent anterior or posterior cervical fusion without CC/MCC. These trials typically enroll patients with cervical radiculopathy or myelopathy who meet surgical indications but are otherwise without major complications, and they compare specific perioperative bundles (e.g., tailored hemostatic strategies, standardized anesthesia pathways, and early mobilization protocols) versus usual care. Results are relevant to surgeons, anesthesiologists, and hospital payers because improvements can shorten operative time, reduce transfusions and ICU needs, and lower index hospitalization costs and resource utilization for this DRG.
Comparative effectiveness and device/technique trials: randomized or pragmatic studies comparing different surgical approaches, fusion constructs, or adjunct technologies (for example anterior cervical discectomy and fusion versus cervical arthroplasty approaches, or different plating and graft options) in patients without major comorbid complications. These trials focus on metrics such as fusion success, reoperation rates, functional outcomes, and short-term inpatient complications over 30–90 days, enrolling typical DRG 473 patients with degenerative cervical disease. Findings inform surgeons and payers about which techniques yield better outcomes or lower complication and readmission rates for this relatively straightforward fusion population, influencing procedure selection, implant procurement, and bundled-payment pathways.
Post-discharge recovery, rehabilitation, and cost-outcomes studies: prospective cohort or randomized studies evaluating discharge timing, outpatient rehabilitation intensity, pain management strategies (including multimodal opioid-sparing regimens), and home health utilization for patients discharged after cervical fusion without CC/MCC. These studies enroll patients who had uncomplicated cervical fusion and examine recovery trajectories, functional status, opioid consumption, readmissions, and total 30–90 day costs to determine optimal post-acute care pathways. This research is important to providers and payers because it identifies interventions that can reduce readmissions, improve return-to-work rates, and optimize post-acute spending for patients in this DRG.

OpenPayer

Summary & Overview

Cervical Spinal Fusion without CC/MCC: Inpatient Reimbursement Overview

DRG 473 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes